Intuitive Surgical’s consistent earnings beats and strong procedure growth position it for significant gains before its next report.
Intuitive Surgical (NASDAQ:ISRG) shares trade 27% below a $560 target, suggesting 35% upside before its July 16 earnings release. The stock currently sits at $413.58, down 26.71% year-to-date, while Wall Street’s average target is $563.35, supported by 22 buy ratings and only 2 sell ratings.
The company has beaten earnings for four consecutive quarters, including a 18.66% non-GAAP EPS beat in Q1 2026 at $2.50 versus a $2.11 consensus. Revenue grew 23% year-over-year to $2.77 billion, with operating income surging 47.95%. Da Vinci procedures rose ~16%, while Ion procedures climbed ~39%, reflecting strong demand.
Intuitive Surgical’s installed base of 11,395 da Vinci systems and 1,041 Ion systems generated $1.69 billion in Q1 instruments and accessories revenue, underscoring its competitive edge over rivals like Medtronic’s Hugo platform.